Shang Hai Zheng Quan Bao·2025-12-01 20:39Core Viewpoint - The announcement details the share reduction results of Beijing Zhaoyan New Drug Research Center Co., Ltd. by its directors, supervisors, and senior executives, confirming compliance with relevant regulations and the completion of the planned share reduction. Group 1: Shareholding Situation Before Reduction - As of September 9, 2025, prior to the reduction plan announcement, the shareholdings of key personnel were as follows: - Sun Yunxia: 2,698,907 shares (0.3601% of total shares) - Gao Dapeng: 288,746 shares (0.0385%) - Gu Jingliang: 269,801 shares (0.0360%) - Li Ye: 102,481 shares (0.0137%) - Yu Aishui: 34,104 shares (0.0046%) - Shares originated from pre-IPO restricted shares, equity incentives, and capital reserve transfers [2] Group 2: Implementation Results of the Reduction Plan - The reduction plan was disclosed on September 9, 2025, and the actual reduction occurred from September 30 to November 28, 2025, with the following reductions: - Sun Yunxia: reduced 319,940 shares - Gao Dapeng: reduced 25,500 shares - Gu Jingliang: reduced 66,509 shares - Li Ye: reduced 2,000 shares - Yu Aishui: reduced 8,500 shares - Total reduction amounted to 422,449 shares, which is 0.0565% of the total shares [3][5] Group 3: Compliance and Plan Execution - The reduction plan was executed in accordance with relevant laws and regulations, and the actual reductions met the previously disclosed plan without any violations or early terminations [5][6]